For that, we combined CTC immunoisolation based on EpCAM expression, accurate RNA extraction from a very low number of cells, whole-genome amplification, and a massive gene-expression profiling for the characterization of the biology of CTC, as we previously described for colorectal and lung cancer [15,16]. This evidence concerns the gene EPCAM and lung cancer.